| 颜美莹,张清媛.他莫昔芬诱发的非酒精性脂肪性肝病的研究进展[J].中国肿瘤,2017,26(3):214-218. |
| 他莫昔芬诱发的非酒精性脂肪性肝病的研究进展 |
| Research Progress in Tamoxifen-induced Nonalcoholic Fatty Liver Disease |
| 投稿时间：2016-03-29 |
| DOI：10.11735/j.issn.1004-0242.2017.03.A010 |
|
 |
| 中文关键词: 他莫昔芬 非酒精性脂肪性肝病 乳腺癌 |
| 英文关键词:tamoxifen nonalcoholic fatty liver disease (NALFD) breast cancer |
| 基金项目: |
|
| 摘要点击次数: 1780 |
| 全文下载次数: 527 |
| 中文摘要: |
| 摘 要：他莫昔芬是治疗激素受体阳性乳腺癌的一种抗雌激素类药物，被广泛地应用于临床。国内外的许多临床研究和动物实验已经证实他莫昔芬可以诱发非酒精性脂肪性肝病。全文主要对他莫昔芬的治疗现状及其诱发的非酒精性脂肪性肝病的流行病学、发病机制、诊断、预测因素、对乳腺癌预后的影响以及预防和管理进行系统全面的综述。 |
| 英文摘要: |
| Abstract：Tamoxifen is a widely used anti-estrogen drug for hormone receptor positive breast cancer patients. Many domestic and international animal studies and clinical researches have proved that tamoxifen can induce nonalcoholic fatty liver disease(NAFLD). This paper reviews the research progress on current status of tamoxifen treatment，the epidemiology，pathogenesis，diagnosis，prevention and management of tamoxifen-induced NAFLD，predictive factors of NAFLD and the relationship between NAFLD and survival outcomes in patients with breast cancer who were treated with tamoxifen. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |